

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	

If you wish to add additional U.S. Published Application citation information please click the Add button

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T5

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

/J.H./	1	CARLUCCI, Michael A., et al. The Endothelin-A Receptor Antagonist Atrasentan (ABT-627) Delays Clinical Progression in Hormone Refractory Prostate Cancer: a Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting.	<input type="checkbox"/>
	2	CHIAO, JW, et al., Endothelin-1 from Prostate Cancer Cells is Enhanced by Bone Contact which Blocks Osteoclastic Bone Resorption, British Journal of Cancer, 2000, pp. 360-365, vol. 83(3).	<input type="checkbox"/>
↓ /J.H./	3	CHIRGWIN, J.M., et al., Tumor-bone Cellular Interactions in Skeletal Metastases, J Musculoskel Neuron Interact 2004, pp. 308-318, vol. 4(3).	<input type="checkbox"/>
	4	EIZATI, Karim. <u>The Effects of Endothelin-1 and Abt-627, an Endothelin-1 Antagonist, in an inVitro Model of Bone Metastases from Prostate Cancer</u> , Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting. No copy provided	<input type="checkbox"/>
	5	GOISE, Theresa. <u>Endothelin A Receptor Blockade Inhibits Osteoblastic Metastases</u> , Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting. No copy provided	<input type="checkbox"/>
/J.H./	6	JAMES, N.D., et al., ZD4054, A Potent, Specific Endothelin A Receptor Antagonist, Improves Overall Survival in Pain-Free or Mildly Symptomatic Patients with Hormone-Resistant Prostate Cancer (HRPC) and Bone Mestastases, European Journal of Cancer Supplements, 2007, p.3, vol. 5, no. 6.	<input type="checkbox"/>
	7	NELSON, Joel B, et al. <u>The Endothelin-A Receptor Antagonist Atrasentan (ABT-627) Reduces Skeletal Remodeling Activity in Men with Advanced, Hormone Refractory Prostate Cancer</u> , Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting. No copy provided	<input type="checkbox"/>
	8	VENUTI, Aldo et al., ABT-627: An Endothelin A Receptor Antagonist as New Antitumor Agent in HPV Associated Cervical Carcinoma, Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting. No copy provided	<input type="checkbox"/>
/J.H./	9	WARREN, Ruth, et al., ZD4054: A Specific Endothelin A Receptor Antagonist with Promising Activity in Metastatic Castration-Resistant Prostate Cancer, Expert Opinion, Investig. Drugs, 2008, pp. 1237-1245, vol. 17(8).	<input type="checkbox"/>
/J.H./	10	YUEN, K.K. Bisphosphonates for advanced prostate cancer (Review), The Cochrane Collaboration, The Cochrane Library, 2008, pp. 1-34, Issue 2.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

EXAMINER SIGNATURE

Examiner Signature	/Julie Ha/	Date Considered	12/04/2008
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.